Half-year report · HY
4572.TEDINET S100YV1G
Period2026-01-01 → 2026-06-30
Filed2026-08-07
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥401m | 2026-01-01 → 2026-06-30 | Cons. | Net sales |
| Revenue | ¥579m | 2025-01-01 → 2025-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥251m | 2025-01-01 → 2025-06-30 | Cons. | Net sales |
| Operating income | −¥954m | 2026-01-01 → 2026-06-30 | Cons. | Operating income |
| Operating income | −¥1.1bn | 2025-01-01 → 2025-06-30 | Cons. | Operating income |
| Ordinary income | −¥1.0bn | 2026-01-01 → 2026-06-30 | Cons. | Ordinary income |
| Ordinary income | −¥2.1bn | 2025-01-01 → 2025-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.1bn | 2025-01-01 → 2025-06-30 | Cons. | Ordinary income |
| Profit before tax | −¥1.0bn | 2026-01-01 → 2026-06-30 | Cons. | Income before income taxes |
| Profit before tax | −¥1.1bn | 2025-01-01 → 2025-06-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥1.0bn | 2026-01-01 → 2026-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥2.2bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥1.1bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥1.0bn | 2026-01-01 → 2026-06-30 | Cons. | Profit loss |
| Net income | −¥1.1bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss |
| Total assets | ¥1.8bn | at 2026-06-30 | Cons. | Assets |
| Total assets | ¥1.2bn | at 2025-12-31 | Cons. | Assets |
| Total assets | ¥1.6bn | at 2025-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥2.2bn | at 2026-06-30 | Cons. | Liabilities |
| Total liabilities | ¥920m | at 2025-12-31 | Cons. | Liabilities |
| Net assets / equity | −¥408m | at 2026-06-30 | Cons. | Net assets |
| Net assets / equity | ¥309m | at 2025-12-31 | Cons. | Net assets |
| Net assets / equity | ¥1.4bn | at 2025-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.1bn | at 2026-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥517m | at 2025-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.1bn | at 2026-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥517m | at 2025-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2025-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.1bn | at 2024-12-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥915m | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥2.2bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥995m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥11m | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥25m | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥16m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.5bn | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥605m | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥14m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-53.13 | 2026-01-01 → 2026-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-113.62 | 2025-01-01 → 2025-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-55.29 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | -23.9% | at 2026-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 25.1% | at 2025-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.1% | at 2025-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 8
| Segment | Item | Period | Value |
|---|---|---|---|
| Drug Discovery Businessreportable segment | segment profit | 2026-01-01 → 2026-06-30 | −¥1.0bn |
| Drug Discovery Support Businessreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥401m |
| Drug Discovery Support Businessreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥401m |
| Drug Discovery Support Businessreportable segment | segment profit | 2026-01-01 → 2026-06-30 | ¥67m |
| Drug Discovery Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥1.0bn |
| Drug Discovery Support Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥251m |
| Drug Discovery Support Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥251m |
| Drug Discovery Support Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥51m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 442
| Item | Context | Value | Unit |
|---|---|---|---|
| Cash and cash equivalents | Prior1InterimInstant | 1060569000 | JPY |
| Cash and cash equivalents | InterimInstant | 1100479000 | JPY |
| Allowance for doubtful accounts accounts receivable trade | Prior1YearInstant | 847000 | JPY |
| Allowance for doubtful accounts accounts receivable trade | InterimInstant | 879000 | JPY |
| Research and development expenses sga | Prior1InterimDuration | 903056000 | JPY |
| Research and development expenses sga | InterimDuration | 926865000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 251097000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration | 251097000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration | － | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 251097000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Net sales | Prior1InterimDuration | 251097000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | -51329000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | -1001512000 | JPY |
| Operating income | Prior1InterimDuration | -1052841000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 401154000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Revenues from external customers | InterimDuration | 401154000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | InterimDuration | － | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 401154000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Net sales | InterimDuration | 401154000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 66809000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | -1020921000 | JPY |
| Operating income | InterimDuration | -954112000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の5第1項の表の第1号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)近畿財務局長 | |
| Filing date cover page | FilingDateInstant | 2026-08-07 | |
| Semi annual accounting period cover page | FilingDateInstant | Original text (Japanese)第24期中(自 2026年1月1日 至 2026年6月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)カルナバイオサイエンス株式会社 | |
| Company name in english cover page | FilingDateInstant | Carna Biosciences, Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 吉野公一郎 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)神戸市中央区港島南町一丁目5番5号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)078-302-7039（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役経営管理本部長 山本詠美 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)神戸市中央区港島南町一丁目5番5号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)078-302-7039（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役経営管理本部長 山本詠美 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E00987 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45720 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)カルナバイオサイエンス株式会社 | |
| Filer name in english | FilingDateInstant | Carna Biosciences, Inc. |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |